India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, By Service (API and Intermediates, and Finished Dose), By Molecule (Small Molecule and Large Molecule), By Drug Type (Monoclonal Antibodies, Insulin, Cytokines, Blood Factors, vaccines and Others), By Container Type (Bottles, Ampoules, Vials, Prefilled Syringes and Others), By Application (Cancer, diabetes, Cardiovascular Diseases, Infectious Disease, CNS and Others), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

India is a favorable sourcing destination for injectables and has many potential injectable CMOs with U.S. FDA/EU GMP-approved facilities capable of exporting to developed markets. A few big pharma companies have already partnered with Indian CMOs for their injectable requirements for the U.S., Europe, and other markets. Therefore, other pharma companies can capitalize on this and partner with Indian CMOs to export injectables to developed markets. Many countries are looking at reducing their healthcare expenditures. To achieve this, developed markets are looking at India to supply injectable drugs at lower prices. In the future, this could lead more CMOs to obtain U.S. FDA/EU GMP certifications for their facilities, and help drive the growth of the Indian injectables CMO market. The India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market accounted for US$ 1,845.62 million in 2019 and is estimated to be US$ 6,557.05 million by 2030 and is anticipated to register a CAGR of 6.3%.

Impact of Covid-19 pandemic on market

COVID-19 is driving many small pharma companies that do not have the expertise or funds to run their own manufacturing facilities to outsource production. COVID-19 vaccine developers are signing contract service agreements at an unprecedented rate, as pharma companies have publicly revealed 42 contract manufacturing service agreements for 28 unique pipeline COVID-19 vaccines, as manufacturing companies benefit from the inflow of governmental grants.

Increasing Prevalence of Chronic Diseases

Chronic diseases and conditions are on the rise worldwide. An ageing population and changes in societal behaviour are contributing to a steady increase in these common and costly long-term health problems. The middle class is growing; and with urbanisation accelerating, people are adopting a more sedentary lifestyle. This is pushing obesity rates and cases of diseases such as diabetes upward. According to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Emerging markets will be hardest hit, as population growth is anticipated be most significant in developing nations. Increased demand on healthcare systems due to chronic disease has become a major concern.

Expansion in Service offering of CMOs

In order to adapt to the paradigm shift in the biotechnology industry and the present biopharmaceutical industry trends, CMOs have decided to move away from solely renting manufacturing units to a business model that offers extensive development and production support. CMOs and contract development and manufacturing organizations (CDMO) individually or together have started offering many specialized, value-added services for customers with early-stage development needs and for those who require support to generate a biologics license application (BLA) enabling process validation data package.

                           Capacity Utilization Issues Affecting the profitability of CMOs

Capacity constraints are still a problem in the pharmaceutical industry, and almost 6 in 10 bio-manufacturers face minor constraints at some stage of manufacturing. Capacity utilization information is important for planners and investors, as they determine whether capacity will be available for the production of pipeline drugs that may be nearing approval. The bio-pharma segment tends to aggressively avoid unanticipated high production demands that can create a capacity crunch. However, CMOs appear to be less afflicted by significant constraint issues compared to bio-therapeutic developers.

Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.

Source: Prophecy Market Insights

The India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is segmented based on Service, molecule, drug type, container type, application, and region.

On the basis of service, the India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is segmented into API and Intermediates and finished dose. Based on site of molecule, the target market is segmented into Small molecule and Large molecule. On the basis of drug type, the target market is segmented into Monoclonal Antibodies, Insulin, Cytokines, Blood Factors, vaccines and Others. On the basis of container type, the target market is segmented into Bottles, Ampoules, Vials, Prefilled Syringes and Others. On the basis of application, the target market is segmented into Cancer, diabetes, Cardiovascular Diseases, Infectious Disease, CNS and Others.

Regional Insights:

On region the India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the region due to a high prevalence of infectious diseases in the region are some factors that are anticipated to boost the generic injectables market in the region.

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, The India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market is segmented based on Service, molecule, drug type, container type, application, and region.

India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, By Region:

• • • North America
      • • U.S.
        • Canada
    • Europe
      • • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • • GCC
        • Israel
        • South Africa
        • Rest of Middle East & Africa

The key players operating in the India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market includes AMRI India Pvt Ltd, Cadila Healthcare Ltd., MSN LAboratories, Farbe Firma, Gland Pharma, Jubilant Life Sciences Limited, Recipharm, Patheon, Kilitch Drugs India limited, and Dr. Reddy’s Laboratories.

• AMRI India Pvt Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Cadila Healthcare Ltd.
• MSN LAboratories
• Farbe Firma
• Gland Pharma
• Jubilant Life Sciences Limited
• Recipharm
• Patheon
• Kilitch Drugs India limited
• Dr. Reddy’s Laboratories

 “*” marked represents similar segmentation in other categories in the respective section